Navigation Links
Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports

Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 /PRNewswire/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, New Products & Services, Surveys, Polls and Research Click to view news release full screen  

Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports


DALLAS, September 28, 2010 /PRNewswire/ -- ReportsandReports announces it will carry Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Research Report in its store.

Browse the complete Report on: forecasts-developments-and-pipeline-an.html

Search More Than 50000 Market Research Reports at ReportsandReports (

Browse All Kalorama Information Research Reports at

Kalorama has been researching and examining the development of cancer vaccines for seven years. In April 2010, the cancer vaccine market experienced one of the biggest achievements in the therapeutic vaccine treatment of cancer-the approval of the prostate cancer vaccine PROVENGE (TM). This, in addition to the success of cervical cancer vaccine products, has created a viable market for what was merely a speculative area just one decade ago.

Even with achievements for some companies, numerous vaccines with apparently strong prospects have been hit by developmental delays and failures. These include CancerVax's Canvaxin, Aphton's Insegia, Progenics' GMK vaccine, and Biomira's Theratope. Despite setbacks many developers are hopeful of a turnaround. With a couple prophylactic vaccines for cervical cancer on the market, a few select therapeutic vaccine approvals and several therapeutic vaccines on a promising path to commercialization, the market could see a surge of regulatory activity and an influx of market opportunities.

This Kalorama Information report - Emerging Cancer Vaccines: Forecasts, Developments and Pipeline Analysis - focuses on both preventive and therapeutic cancer vaccines in development. The following cancers for which there are vaccines in development or where there is a potential are profiled:

- Cervical - Colon/Rectal - Lung - Lymphoma - Melanoma - Prostate - Breast - Gastrointestinal - Renal - Brain - Bladder - Ovarian - Leukemia

The report includes statistical information for cancers by type worldwide, with special emphasis on the U.S. market. Specifically, cancers where there is current vaccines development are profiled. Each market segment provides an overview, descriptions of products available or in development, market estimates and forecasts for 2010-2015, and competitive analysis of leading developers for 2015.

The report also includes current issues and trends affecting the industry.

This area of medicine is a new frontier and many of the issues that face the cancer vaccine market are novel. However, this is a very promising area of medicine, which will continue to assist in the fight against cancer.

Issues and trends discussed in The Emerging Cancer Vaccine Market include: - Early Detection and Screening - Monoclonal Antibodies and Therapeutic Vaccines - Safety Concerns - Insurance and Reimbursement Issues - Personalized Medicine - Pharmacogenomics - Vaccine Strategies - Economic Conditions and Vaccine Discovery

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information.

For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and development representatives.

All market data pertains to the world market at the manufacturers' level. The years outlined in this study include projected markets for 2010 thru 2015. Compound annual growth rates (CAGRs) are provided for the 2010-2015 for each vaccine segment covered. Competitive analysis is provided for the year 2015 for the developing and emerging market. The projected competitive analysis for 2015 was based on products in late stage development, probability of approval and marketing, and demographic trends.

Several companies have promising research and development activities for cancer vaccines. Additionally, many companies are in early stage development with a focused effort on providing favorable results in treating cancer. Many of these companies are:

- Accentia - Antigenics - AVAX - Dendreon - GlaxoSmithKline - Merck & Co. - Northwest Biotherapeutics - Oncothyreon - Vaccinogen Browse all Healthcare Reports at Browse All Specific Markets: Browse All Latest Reports: Browse All Cancer Vaccine Reports:

About Us

ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

(Due to the length of these URLs, it may be necessary to copy and paste the hyperlinks into your Internet browser's URL address field. Remove the space if one exists.)

Contact: Ms. Sunita 7557 Rambler road, Suite 727, Dallas, TX 75231 Tel: +1-888-989-8004

SOURCE MarketsandMarkets
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
2. Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service
3. Malaria Vaccine Developer Sanaria Inc. Receives the Technology Council of Marylands Emerging Company of the Year Award
4. Current and Emerging Drugs Continue to Struggle for Patient Share in the Treatment of Major Depressive Disorder
5. Emerging Therapies Could Help Ease The Chronic Symptoms of Atopic Dermatitis For Adults and Children
6. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
7. At Nearly $120 Million, The Hepatitis C Drug Market in Brazil is Among the Largest Emerging Pharmaceutical Markets for the Disease
8. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
9. Patient-Targeted Messaging for Emerging Multiple Sclerosis Agents Needs to Highlight Efficacy and Preservation of Quality of Life
10. Frost & Sullivan Lauds Viatronix as European Medical Imaging Emerging Company of the Year
11. Cancer Drugs Emerging as Top Driver of Specialty Drug Spending
Post Your Comments:
(Date:6/26/2016)... LAS VEGAS , June 26, 2016 ... movement to value-based care operating models within the health ... that enable greater financial efficiency , Deloitte offers ... address the key business issues impacting efficient cost optimization: ... alignment , These services facilitate better outcomes and ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: ... and sells medical devices and wearable sleep respiratory products ... cooperation agreement with Hongyuan Supply Chain Management Co., Ltd. ... 20, 2016, to develop Dehaier,s new Internet medical technology ... will leverage Hongyuan Supply Chain,s sales platform to reach ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... , ... TherapySites, the leading website and online ... Counseling Association. This new relationship allows TherapySites to continue to extend their ... benefits and promotional offers. , "TCA is extremely excited about this new partnership, ...
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
Breaking Medicine News(10 mins):